Clinical Pearls for the Treatment of AD
Expert dermatologists share clinical pearls for providers treating patients with AD, and discuss the future of AD treatment.
Read More
Access to JAK Inhibitors in AD
Lisa Swanson, MD, PhD, highlights dermatology biologics coordinators as a resource for getting better access to JAK inhibitors.
Utilizing JAK Inhibitors in Clinical Practice
Dermatology experts discuss the use of JAK inhibitors in clinical practice, highlighting their own experiences and use of JAKs alongside corticosteroids.
Treatment Selection of JAK Inhibitors for the Management of AD
Expert dermatologists speak on shared-decision making between the patient and the provider when it comes to selecting the right therapy for AD.
Contraindications for Use of JAK Inhibitors in AD
Peter Lio, MD, reviews the contraindications of JAK inhibitors in AD and approaches for monitoring patients who are prescribed a JAK inhibitor.
Boxed Warnings for JAK Inhibitors in AD
Alexandra Golant, MD, comments on the boxed warnings on all currently approved JAK inhibitors, as well as the commonly used treatments in dermatology that have boxed warnings.
Safety of JAK Inhibitors Approved for AD Treatment
Expert dermatologists review the safety data of the current JAK inhibitors approved for AD, highlighting adverse events and long-term safety data.
Indications and Efficacy of JAK Inhibitors for AD
Lisa Swanson, MD, PhD, reviews the indications for ruxolitinib, abrocitinib, and upadacitinib, as well as the clinical trial data on efficacy of these JAK inhibitors when treating AD.
Differentiating JAK Inhibitors From Other Therapies in AD
Expert dermatologists discuss the factors that differentiate JAK inhibitors from other AD therapies, highlighting itch scores as they relate to quality of life.
Targeting the JAK-STAT Pathway in AD
Alexandra Golant, MD; Christopher Bunick, MD, PhD; and Peter Lio, MD, comment on how targeting the JAK-STAT (signal transducer and activator of transcription) pathway with JAK inhibitors plays a role in managing AD.
Intro to Janus Kinase (JAK) Inhibitors for Treatment of Atopic Dermatitis (AD)
Peter Lio, MD, and Lisa Swanson, MD, PhD, provide an overview of Janus Kinase (JAK) inhibitors, their pathophysiology, and their mechanism of action in the treatment of atopic dermatitis (AD).
Achieving Durable Clinical Response with Targeted Treatment for Vitiligo
In this MEDcast episode, Dr Chovatiya and Dr Bunick delve into the advancements in targeted treatments for vitiligo, exploring their potential to provide long-term efficacy and durable clinical response.
Achieving Durable Clinical Response with Targeted Treatments for Vitiligo
Novel Systemic and Topical Treatment for Plaque Psoriasis
In this episode of MEDcast, expert dermatologists discuss exciting advancements in systemic therapies such as JAK inhibitors, and the latest breakthroughs in topical treatments for plaque psoriasis
Novel Systemic and Topical Treatments for Plaque Psoriasis
In this episode of MEDcast, expert dermatologists discuss exciting advancements in systemic therapies such as JAK inhibitors, and the latest breakthroughs in topical treatments for plaque psoriasis.
AD Clinical Approach: Switching Therapies
Christopher G. Bunick, MD, PhD, shares their clinical approach for switching therapies for atopic dermatitis (AD) treatment.
RAD 2023 AD Trial: Meta-Analysis Data
A dermatology expert provides an overview of the results of the meta-analysis data from the RAD 2023 atopic dermatitis (AD) trial.
AD: Efficacy Outcomes
Christopher G. Bunick, MD, PhD, discusses underutilized efficacy outcomes in atopic dermatitis (AD) clinical trials.
NRS in AD Treatment
A dermatology expert discusses how numerical rating scale (NRS) is used in atopic dermatitis (AD) clinical trials.
EASI Scores in AD Treatment
A dermatology expert discusses how the standard of care EASI scores have been improving with newer atopic dermatitis (AD) therapies.
Clinical Outcomes in AD Clinical Trials
Christopher G. Bunick, MD, PhD, provides an overview of clinical trial outcomes in atopic dermatitis (AD).
Standard of Care in AD
Christopher G. Bunick, MD, PhD, discusses what can be done to improve the standard of care for atopic dermatitis (AD).
